Clinical Trial Update: Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib [Phase 3]

View source ↗

Summary

Phase 3 trial comparing alectinib to pemetrexed or docetaxel in ALK-positive NSCLC patients previously treated with platinum-based therapy and crizotinib; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)
• Crizotinib (crizotinib)
• DOCETAXEL (DOCETAXEL)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-02-26